Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.
InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.
InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.
Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.
In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.
InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.
For more detailed information and the latest updates, visit InMode's official website.
InMode Ltd. (Nasdaq: INMD), a leader in medical technology, announced that its CFO, Yair Malca, will present at the Jefferies Virtual Healthcare Conference on June 4 at 10:30 a.m. ET. Malca will also be available for one-on-one virtual meetings during the event. A live webcast of the presentation can be accessed here and will be archived for 30 days. InMode specializes in innovative RF technology for various medical fields, including plastic surgery and dermatology.
InMode Ltd. (Nasdaq: INMD) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 26 at 10:00 a.m. ET. Key executives, including CEO Moshe Mizrahy and CFO Yair Malca, will engage in discussions and be available for one-on-one meetings. The live webcast can be accessed on InMode's investor relations site, with an archive available for 30 days post-event. InMode specializes in innovative medical technologies utilizing RF technology across various medical fields.
InMode Ltd. (Nasdaq: INMD) reported a robust first quarter for 2021 with revenues of $65.5 million, a 62% year-over-year increase. The company's GAAP net income surged to $26.6 million or $0.63 per diluted share, up from $6.4 million and $0.15 respectively in Q1 2020. The high performance was driven by increased demand for minimally invasive technologies, particularly consumables which tripled over the last year. For 2021, InMode anticipates revenues between $270 million and $280 million and non-GAAP EPS between $2.60 and $2.75.
InMode Ltd. (Nasdaq: INMD) announced it will release its Q1 2021 financial results on May 5, 2021. Preliminary estimates indicate revenue between $65.0 million and $65.4 million, with non-GAAP earnings per diluted share ranging from $0.65 to $0.67. The expected non-GAAP gross margin for 2021 is between 84% and 86%. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss these results. InMode specializes in innovative medical technologies, prominently using RF technology.
InMode Ltd. (Nasdaq: INMD) announced that key executives will present at the Needham 20th Annual Virtual Healthcare Conference on April 13, 2021, at 11:45 am EDT. The presentation will include insights from Mr. Moshe Mizrahy, Dr. Michael Kreindel, Mr. Yair Malca, Dr. Spero Theodorou, and Mr. Shakil Lakhani. Following the presentation, management will be available for one-on-one investor calls. A live webcast of the presentation will be accessible on the company's investor page, archived for 90 days. InMode specializes in innovative medical technologies, focusing on minimally-invasive RF devices.
InMode Ltd. (Nasdaq: INMD) has filed a complaint with the U.S. International Trade Commission, alleging that ILOODA's SecretRF microneedling system infringes on its U.S. Patent No. 10,799,285. InMode seeks an investigation into the infringement and an exclusion order against the importation of SecretRF. InMode's Chief Technology Officer emphasized the company's commitment to defending its intellectual property, which plays a crucial role in its strategic growth and innovation in minimally invasive medical technologies.
InMode Ltd. (Nasdaq: INMD) reported record financial results for Q4 2020 and the full year, driven by a 60% revenue increase to $75.2 million in Q4 and a 32% increase to $206.1 million for the year. The company achieved a GAAP net income of $36.1 million in Q4, up from $19.0 million in Q4 2019. For 2020, GAAP net income was $75.0 million, compared to $61.1 million in 2019. The company projects 2021 revenues of $250 million to $260 million, with non-GAAP earnings per diluted share expected between $2.34 and $2.45.
On January 12, 2021, InMode Ltd. (Nasdaq: INMD) announced its expectation for record revenues in Q4 2020, projected between $74.5 million to $75 million, and a full-year total of $205.5 million to $206 million. This surpasses prior guidance of $192 million to $195 million. Non-GAAP earnings per diluted share are expected to be $0.91 to $0.93 for Q4 and $2.08 to $2.10 for the full year. Additionally, the company provided a revenue guidance of $250 million to $260 million for 2021.
InMode Ltd. (Nasdaq: INMD) announced its participation in the 2021 ICR Conference held virtually from January 11-14, 2021. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will engage in a fireside chat on January 14, 2021, at 3:15 pm EST. A live webcast will be accessible to the public and archived for 90 days post-event. InMode specializes in innovative medical technologies utilizing radio-frequency (RF) technology, enhancing surgical procedures across multiple medical fields.
InMode Ltd. (Nasdaq: INMD) is set to present its corporate social responsibility (CSR) strategy in its annual 20-F filing, highlighting sustainable practices as it expands into new markets. The strategy aims to enhance local economies and stakeholder engagement. The first CSR report will focus on Product Safety and Supply Chain Management, aligning with sustainability metrics outlined by the SASB. CEO Moshe Mizrahy emphasized the company's commitment to safe, non-invasive medical devices that improve patient quality of life.
FAQ
What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?
What is the market cap of InMode Ltd. Ordinary Shares (INMD)?
What products does InMode Ltd. offer?
What are InMode's core business categories?
Which markets does InMode serve?
How did InMode perform in Q3 2023?
What are some of InMode's flagship products?
What recent legal actions has InMode taken?
What new platforms has InMode recently announced?
Who is the new Chairman of InMode's Board?
What partnership has InMode recently entered into?
Where can I find more information about InMode?
